Citations 3
International development of Investigator Global Assessment scores for pemphigus
Murrell, Dédée F., Boucher, Darby , Daneshpazhooh, Maryam, Mahmoudi, H., Kianfar, Nika , Wilson, Anna , BILGIC, ASLI, Chandran, N. S., Patsatsi, Aikaterini , Caux, Frédéric, Lim, Yen L., Marzano, Angelo V., Payne, Aimee S., Sprecher, Eli, Beek, Nina Van, Yamagami, Jun , Antiga, Emiliano, Bagci, I., Borradori, Luca, Caproni, Marzia, De, Dipankar, Dunn, Patrick F. , Feliciani, Claudio, Fivenson, David , Handa, Sanjeev, Horvath, B., Ioannides, D. , Kasperkiewicz, Michael, Lipman, Rachel E. , Mascaró, José M., Meijer, Joost M. , MIMOUNI, D, Schultz, Brittney , Skiljevic, Dusan, Strong, Becky, Tomayko, Mary M. , Vestergaard, Christian , Wozniak, Katarzyna, Yayli, S., Joly, Pascal, Werth, Victoria P., Caproni, Marzia , Joly, P. , Horváth, Barbara , Murrell, D F , Daneshpazhooh, M , Mahmoudi, Hamidreza , Wilson, Anna , Patsatsi, Aikaterini , Drenovska, Kossara , Caux, Frédéric , Marzano, Angelo Valerio , Schmidt, Enno , Sprecher, Eli , Van Beek, Nina , Antiga, Emiliano , Borradori, Luca , Caproni, Marzia , Feliciani, Claudio , Ioannides, Dimitrios , Kasperkiewicz, Michael , Mascaró, José M , Meijer, Joost M , Schultz, Brittney , Vestergaard, Christian , Joly, Pascal , Dasdar, Shayan , Yale, Marc , Uzun, Soner , Vassileva, Snejina , Culton, Donna Aline , Hertl, Michael , Marinović, Branka , Marzano, Angelo Valerio , Payne, Aimee S. , Schmidt, Enno , Sprecher, Eli , Bağci, Işın Sinem , Corrà, Alberto , De, Dipankar , Dunn, Patrick, Günther, Claudia , Handa, Sanjeev , Kowaléwski, Cezary , Lehman, Julia S. , Mimouni, Daniel , Skiljevic, Dusan S. , Woźniak, Katarzyna , Yaylı, Savaş , Werth, Victoria P.
Journal of the European Academy of Dermatology and Venereology | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
Garg, Amit , Strunk, Andrew , Midgette, Bria, Frasier, Kelly , Cohn, Erica, Aarts, Pim , Alhusayen, Raed , Bechara, Bitte Falk G., Brassard, Alain, Brown, Debra, Emtestam, Lennart , Benhadou, Farida , Fernández‐Peñas, Pablo , Gebauer, Kurt , Horváth, Barbara , Marzano, Angelo Valerio , Orenstein, Lauren A.V. , Pascual, J.C. , Piguet, Vincent, Resnik, Barry I., Roth, Gretchen M. , Straalen, Kelsey van, Ingram, John R , Ingram, J R , Garg, Amit, Cohn, Erica, Alavi, Afsáneh , Bettoli, Vincenzo , Chandran, Nisha Suyien , Choon, Siew Eng , Cohen, Steven R. , Daveluy, Steven , Mármol, V. del , Dellavalle, Robert Paul , Flowers, Richard Hal , Frew, John W. , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Hsiao, Jennifer L. , Jemec, Gregor B. E. , Lowes, Michelle A , Matusiak, Łukasz , Micheletti, Robert , Oon, Hazel H. , Ortega‐Loayza, Alex G. , Paek, So Yeon , Rosmarin, David M. , Sayed, Christopher J. , Silva, Dimitri Luz Felipe da , Thorlacius, Linnea , Tzellos, Thrasyvoulos , Zee, Hessel H. van der , Straalen, Kelsey R. van , Ingram, John R.
JAMA Dermatology | November 26, 2025 | Volume: 162 | Issue: 1 | Pages: 72
10.1001/jamadermatol.2025.4652
Importance Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. Objective To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Evidence Review Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Findings Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Conclusions and Relevance Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings.
Yao syndrome: a novel systemic autoinflammatory disease with cutaneous manifestations
Shakhashiro, Muna , Sadeghian, Shadi, Newcomer, Jack , Marzano, Angelo Valerio , Maronese, Carlo Alberto , Newcomer, Jack B. , Maronese, Carlo A , Sadeghian, Shadi, Davis, John M. , Alavi, Afsáneh
International Journal of Dermatology | July 5, 2024 | Volume: 64 | Issue: 1 | Pages: 44-50
AbstractYao syndrome (YAOS) is a novel systemic autoinflammatory disease linked to the nucleotide‐binding oligomerization domain (NOD2) gene. It is characterized by periodic fevers, gastrointestinal (GI) symptoms, arthritis, and dermatitis, among other symptoms. A sparse literature exists on this disease, and little is known about its dermatological manifestations. A review of available literature was performed to characterize the cutaneous manifestations of Yao syndrome. Cutaneous manifestations were documented in 85.7% of patients, with common characteristic descriptions of erythematous patches and plaques involving the face, trunk, abdomen, and extremities. Based on our review of treatment modalities employed for Yao syndrome, prednisone is an appropriate initial approach, with oral sulfasalazine and other disease‐modifying antirheumatic drugs serving as appropriate secondary options. YAOS should be considered in the differential diagnosis of patients presenting with a dermatitic rash, especially in the context of concurrent articular symptoms, periodic fever, and GI symptoms.